Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, United States; Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, United States.
Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, United States.
J Clin Neurosci. 2020 Nov;81:180-185. doi: 10.1016/j.jocn.2020.09.064. Epub 2020 Oct 12.
Rebleeding after aneurysmal subarachnoid hemorrhage (aSAH) confers a poor prognosis; however, risk factors and differential outcomes associated with early rebleeding in the first 24 h after symptom presentation are incompletely understood.
A retrospective cohort study of all aSAH presenting to our institution between 2001 and 2016 was performed. Early rebleeding events were defined as clinical neurologic decline with radiographically confirmed acute intracranial hemorrhage within 24 h after symptom presentation. Univariate and multivariate logistic regression analyses were used to assess clinical associations, with a specific focus on baseline Glasgow Coma Score (GCS), World Federation of Neurosurgical Societies (WFNS), and modified Fisher scores.
Of 471 aSAH cases, 33 (7%) experienced early rebleeding. Multivariate regression identified extraventricular drain (EVD) placement (OR = 2.16, P = 0.04) and WFNS 3-5 (OR = 2.69, P = 0.02) as significant predictors of early rebleeding. Good functional outcomes were observed in 8 patients with early rebleeding (24%), all of whom underwent aneurysm treatment. Higher SAH grade prior to rebleeding (WFNS 3-5) was significantly associated with increased odds of an unfavorable functional outcome (OR = 8.09, P < 0.01). Anticoagulation, aneurysm size and location were not significantly associated with either early rebleeding incidence or functional outcome.
Early rebleeding in aSAH is associated with unfavorable functional outcomes. EVD placement and higher SAH grade on presentation appear to be significantly and independently associated with increased risk of rebleeding within first 24 h, as well as unfavorable long-term functional outcome; however, the clinical benefit of hyper-acute aneurysm treatment requires further investigation.
动脉瘤性蛛网膜下腔出血(aSAH)再出血预后不良;然而,对于症状出现后 24 小时内早期再出血的风险因素和差异结果尚不完全清楚。
对 2001 年至 2016 年期间我院收治的所有 aSAH 患者进行回顾性队列研究。早期再出血事件定义为症状出现后 24 小时内出现临床神经功能下降并经影像学证实急性颅内出血。采用单因素和多因素逻辑回归分析评估临床相关性,特别关注基线格拉斯哥昏迷评分(GCS)、世界神经外科学会联合会(WFNS)和改良 Fisher 评分。
在 471 例 aSAH 病例中,33 例(7%)发生早期再出血。多因素回归分析发现,脑室外引流(EVD)放置(OR=2.16,P=0.04)和 WFNS 3-5 级(OR=2.69,P=0.02)是早期再出血的显著预测因素。8 例早期再出血患者(24%)功能结局良好,均接受了动脉瘤治疗。再出血前较高的蛛网膜下腔出血分级(WFNS 3-5 级)与不良功能结局的发生几率增加显著相关(OR=8.09,P<0.01)。抗凝、动脉瘤大小和位置与早期再出血发生率或功能结局均无显著相关性。
aSAH 早期再出血与不良功能结局相关。EVD 放置和发病时较高的蛛网膜下腔出血分级似乎与 24 小时内再出血风险增加以及不良长期功能结局显著相关;然而,超急性动脉瘤治疗的临床获益需要进一步研究。